Children who miss early vaccines more likely to not get the MMR shot by age 2: Study

A JAMA Network Open study using Truveta electronic health records of more than 321,000 U.S. children (care between Jan 1, 2018 and Apr 30, 2025) finds that 78.4% received the MMR vaccine on time by age 2, 13.9% were delayed, 1% early, and 6.7% unvaccinated; missing recommended 2-month and 4-month vaccines was the strongest predictor of no MMR dose and on-time 2-month vaccination made children seven times more likely to get MMR. The study notes on-time MMR coverage rose from 75.6% in 2018 to 79.9% in 2021 before falling to 76.9% in 2024, with the share unvaccinated by age 2 increasing from 5.3% in 2020 to 7.7% in 2024, coinciding with the U.S. surpassing 2,000 measles cases — trends that imply rising public-health risk and could prompt policy or provider-level interventions affecting healthcare demand and immunization programs.

Analysis

Market structure: Rising measles cases and falling MMR uptake shift modest positive revenue toward large vaccine makers (Merck MRK), cold-chain/logistics (Thermo Fisher TMO, Cardinal Health CAH) and contract manufacturers (Catalent CTLT). Pediatric providers, urgent-care chains and hospital systems (HCA) see higher short-term visit and admission volumes; insurers face increased claim frequency but limited price power since vaccinations are low-margin and government-driven purchases dominate demand. Expect incremental public procurement contracts (months) rather than material private-price inflation.

Risk assessment: Tail risks include a large localized outbreak prompting emergency federal spending (+$100–$500m state/federal procurements) or litigation/policy backlashes that depress uptake; conversely rapid public education campaigns could restore rates within 6–12 months. Immediate risk (days–weeks) is reputational and operational for providers; medium-term (3–9 months) risk centers on policy responses and supply chain capacity. Hidden dependencies: pediatric clinic throughput, insurer coding/reimbursement and school-mandate legal actions.

Trade implications: Favor small, targeted longs in vaccine and cold-chain stocks (MRK, TMO, CTLT) with defined risk via call spreads; overweight hospital operators with pediatric exposure (HCA) for 3–9 month trade windows. Avoid broad biotech exposure; prefer selective pair trades (healthcare providers vs consumer discretionary) to isolate outbreak-driven demand. Key catalysts: CDC weekly case counts, federal/state vaccine purchase announcements and school-mandate litigation over next 30–90 days.

Contrarian angles: Consensus overweights pure vaccine makers; market may underprice service providers and logistics beneficiaries who capture recurring demand (testing, ED visits, storage). The upside is capped — MMR is inexpensive and supply is elastic — so trades should be small, defined-risk and event-driven (gain if government buys/schools mandate), not long-term thematic bets.

Key Decisions for Investors

• Establish a defined-risk 1–1.5% portfolio position long Merck (MRK) via a 3–6 month call spread (buy MRK Jul 2026 110C / sell 120C) to capture incremental government/school procurement; cap loss at premium paid and target 15–30% upside if CDC announces purchase orders within 90 days.
• Take a 1.5–2% long position in Thermo Fisher Scientific (TMO) stock for 6–12 months to play cold-chain, testing and logistics volume growth; set a tactical stop-loss at -12% and a take-profit at +25% or earlier if weekly CDC case growth rate falls below +5% month-over-month.
• Implement a pair trade: long HCA Healthcare (HCA) 1.0% notional vs short consumer discretionary ETF XLY 1.0% notional for a 3–9 month horizon to express demand shift to acute care; unwind when measles case growth decelerates to <2% monthly or after 6 months if no material state/federal intervention is announced.